Creator: Help Dementia Editorial Team
Published: 2026-04-12T00:11:17

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Healthcare infrastructure sits at the center of this dementia and brain health question.

Healthcare infrastructure investment in Alzheimer’s care is no longer optional—it is a critical necessity that demands urgent federal, state, and institutional commitment. The United States currently spends an estimated $384 billion annually to care for people with Alzheimer’s and other dementias, yet our healthcare system lacks the integrated infrastructure needed to prevent the disease, detect it early, and provide coordinated care across the lifespan. Without significant and sustained investment in research facilities, primary care capacity, diagnostic technology, and long-term care systems, the nation faces a cascade of failures: missed early interventions, overwhelmed providers, and exploding costs that will reach unsustainable levels within a decade.

Congress and the Biden-Harris administration have begun to recognize this reality. In fiscal year 2026, they secured a $100 million increase for Alzheimer’s and dementia research at the National Institutes of Health, bringing total annual federal funding to approximately $3.9 billion, and allocated $41.5 million to implement BOLD Infrastructure—the highest annual investment since the law was enacted. The CDC received a $2 million increase for its Alzheimer’s program, and the administration invested over $200 million to help primary care doctors and nurses improve care for older adults with Alzheimer’s and related dementias. Yet these investments, while meaningful, represent only a fraction of what experts say is needed: $2 billion per year in research funding alone, plus the infrastructure to translate that research into accessible, equitable care for millions of Americans.

Why Current Infrastructure Cannot Meet Alzheimer’s Demand
The Unsustainable Financial Burden Without Infrastructure Investment
Research Infrastructure as the Foundation for Progress
Strengthening Primary Care as Infrastructure for Earlier Detection
The Overlooked Caregiving Infrastructure Crisis
Early Detection Infrastructure and Prevention Pathways
Looking Forward—What Infrastructure Investment Can Achieve
Conclusion

Why Current Infrastructure Cannot Meet Alzheimer’s Demand

The infrastructure gap becomes apparent when examining actual prevalence trends and projected needs. Without a breakthrough, the number of Americans with Alzheimer’s is expected to nearly double by 2050, with 12.7 million people age 65 and older projected to have the disease. Today, approximately 3.2 million Americans live with Alzheimer’s disease, yet our healthcare system was designed for a different era of aging—one with fewer cases, less complexity, and lower diagnostic awareness. Primary care physicians, many of whom lack specialized training in neurodegenerative diseases, bear the burden of initial detection and management without adequate support systems, diagnostic tools, or time built into their practice models.

The current healthcare infrastructure creates a three-stage failure. First, many cases go undiagnosed until moderate or late stages because screening tools and biomarker testing are not integrated into routine primary care visits. Second, when diagnosed, patients often lack access to specialist care; the National Institute on Aging estimates significant geographic disparities, with rural and underserved communities having minimal access to neurologists or geriatric specialists. Third, the system provides little infrastructure for coordinating care across hospital systems, ambulatory clinics, and home health services. An elderly patient might receive a diagnosis at one hospital, struggle to find a memory care specialist who accepts their insurance, and ultimately abandon the healthcare system entirely, relying instead on unpaid family caregivers who lack clinical guidance or respite services.

Why Current Infrastructure Cannot Meet Alzheimer's Demand

The Unsustainable Financial Burden Without Infrastructure Investment

The financial numbers reveal why infrastructure is not a luxury but an economic imperative. The total cost for caring for people with Alzheimer’s and other dementias in 2025 is projected to reach $384 billion, with Medicare and Medicaid covering $246 billion (64%) of that burden—shifting the fiscal pressure onto already-stretched federal and state budgets. For the federal government, this is the equivalent of funding an entire department, yet dementia care infrastructure remains fragmented, underfunded, and largely invisible in public discourse. What makes this unsustainable is the projection of costs absent intervention.

The National Institute on Aging estimates the annual disease burden at $321 billion, including $206 billion in Medicare and Medicaid costs, but these figures assume disease prevalence will grow while nothing fundamentally changes in how care is organized or delivered. Without infrastructure investment—including diagnostic centers, specialized care networks, and prevention programs—each additional case added to the 2050 projection will carry the same organizational chaos and financial burden as cases today. Infrastructure investment, by contrast, enables efficiency. A well-designed regional diagnostic center that performs cognitive screening, blood-based biomarker testing, and imaging can detect Alzheimer’s years earlier than a patient waiting for a specialist appointment, when disease-modifying treatments are more effective. Early detection infrastructure can shift cases from expensive institutional care to managed outpatient care, yielding long-term savings of hundreds of thousands of dollars per patient.

Research Infrastructure as the Foundation for Progress

Federal research infrastructure funding directly determines whether scientists can translate Alzheimer’s knowledge into breakthrough treatments and prevention strategies. The Alzheimer’s Association invested $112.2 million in 2025—the largest single-year investment in its history—supporting over 250 scientific investigations with total active and committed investments exceeding $450 million. Despite this, the National Institute on Aging identified a projected gap of $445 million in FY2026 for research needed to meet National Plan goals, a shortfall that forces researchers to either reduce scope or delay investigations that could yield transformative insights. The recent breakthroughs in early detection illustrate why research infrastructure matters. Blood-based biomarkers—simple tests that can detect Alzheimer’s-related changes from a single blood draw—are now validated and moving into clinical practice.

Digital cognitive assessment tools deployed through smartphones can track subtle changes in memory and processing speed over time, enabling detection of biological changes many years before symptoms appear. None of these advances emerged accidentally; they required federal infrastructure funding for basic research, clinical trial networks, and regulatory pathway validation. Without sustained investment in research infrastructure, these advances stall. The two-year lag between a discovery in a funded laboratory and its appearance in a clinical trial is not random—it reflects the limited infrastructure available to conduct human research. Expanding this infrastructure would compress that timeline, bringing new treatments and prevention strategies to patients faster while potentially saving billions in downstream healthcare costs.

Research Infrastructure as the Foundation for Progress

Strengthening Primary Care as Infrastructure for Earlier Detection

The $200 million invested by the Biden-Harris administration in the Primary Care Initiative represents a crucial recognition that primary care doctors are the frontline detection system for Alzheimer’s disease. Most Americans see their primary care physician annually but visit a neurologist rarely or never. Yet primary care visits are typically 15 to 20 minutes—insufficient time for cognitive screening, risk assessment, and discussion of emerging biomarker testing, unless the infrastructure exists to support these activities. Infrastructure investment in primary care means funding care coordinators, nurse specialists, and digital platforms that enable physicians to manage cognitive assessment alongside their existing obligations.

It means integrating validated screening tools into electronic health records so that cognitive decline can be flagged automatically, drawing the physician’s attention. It means creating pathways for rapid referral to diagnostic services when screening suggests cognitive impairment, rather than leaving the patient to search independently for a neurologist who may have a three-month waiting list. The HHS initiative explicitly targets improvements in care for older adults with Alzheimer’s and related dementias, acknowledging that without primary care infrastructure, federal research advances and FDA-approved treatments never reach the patients who need them. Comparison reveals the gap: in well-resourced integrated health systems with dedicated dementia care pathways, detection of mild cognitive impairment occurs years earlier than in fee-for-service practices without such infrastructure, and subsequent treatment adherence is substantially higher.

The Overlooked Caregiving Infrastructure Crisis

The informal caregiving sector, which represents the backbone of Alzheimer’s care in America, is itself a healthcare infrastructure under extreme stress. Nearly 12 million Americans provide unpaid care for people with Alzheimer’s or dementia, delivering an estimated 19 billion hours of care valued at more than $413 billion annually—far exceeding Medicare’s entire budget for the disease. Yet these 12 million caregivers receive minimal institutional support: few have access to training in how to manage behavioral symptoms, memory loss, or activities of daily living; respite care is scarce and unaffordable; and caregiver burnout is nearly universal. This caregiving infrastructure deficit creates a warning that is often overlooked in policy discussions: family caregivers are increasingly unable to sustain care alone, yet formal long-term care services are expanding slowly and unevenly.

Nursing home bed capacity, assisted living, and adult day programs are geographically concentrated, unequally distributed across income levels, and often unaffordable even with insurance. A family providing care at home for a person with advanced Alzheimer’s faces an impossible choice: exhaust themselves and risk their own health, or pay $50,000 to $100,000 annually for formal services that may be unavailable in their area. Infrastructure investment in caregiver support—training programs, respite services, mental health resources, and care coordination—would not only improve quality of life for caregivers but would delay expensive institutional care, yielding cost savings. Yet this infrastructure remains largely absent from current funding allocations.

The Overlooked Caregiving Infrastructure Crisis

Early Detection Infrastructure and Prevention Pathways

Recent advances in early detection are beginning to shift the paradigm from end-of-life care to prevention, but only if healthcare infrastructure can support it. Blood-based biomarkers can now identify people with Alzheimer’s pathology years before cognitive symptoms appear, and digital cognitive tools enable remote monitoring of subtle changes in thinking speed and memory.

The Alzheimer’s Association and National Institute on Aging have designated this era the “new era in early detection and prevention of cognitive decline,” yet realizing this potential requires infrastructure that most communities lack. A person who receives a blood test showing Alzheimer’s pathology faces a cascade of unmet infrastructure needs: Where do they get counseling about what the result means? Which lifestyle interventions—exercise, cognitive stimulation, sleep optimization, dietary changes—should they prioritize, and who teaches them? How do they access clinical trials testing prevention strategies? Which primary care physicians have the expertise or time to manage asymptomatic people at risk? Early detection infrastructure means building regional cognitive screening centers, training primary care physicians to interpret biomarker results, creating pathways to prevention trials, and funding lifestyle intervention programs. Without this infrastructure, early detection becomes early alarm without early action, causing anxiety and medical costs without benefit.

Looking Forward—What Infrastructure Investment Can Achieve

The investments made in FY2026—$100 million in NIH research funding, $41.5 million for BOLD Infrastructure implementation, $200 million for primary care enhancement—demonstrate that the nation is beginning to move in the right direction. Yet the trajectory remains insufficient. Experts determined that $2 billion per year in research funding is needed to achieve the goal of preventing and treating Alzheimer’s, suggesting that current $3.9 billion in total federal investment must be split and allocated more strategically, with increased emphasis on research infrastructure that supports early detection and prevention research. The coming decade will reveal whether the nation’s infrastructure commitments are sufficient to bend the disease curve.

If current investments are sustained and increased, the infrastructure built in 2026 and beyond could detect Alzheimer’s earlier, enable prevention trials, strengthen primary care’s capacity to manage cognitive health, and create sustainable caregiving support systems. If investments stagnate, the projections of 12.7 million Americans with Alzheimer’s by 2050 will materialize, with attendant costs and human suffering. The choice is not between paying now for infrastructure or avoiding costs—it is between investing in infrastructure that prevents and slows disease, or absorbing astronomical costs for late-stage institutional care. The infrastructure exists to make early detection, prevention, and coordinated care the norm rather than the exception. Whether the nation will fund it remains an open question.

Conclusion

Healthcare infrastructure investment in Alzheimer’s care is the linchpin that determines whether federal research advances, new diagnostics, and emerging treatments reach patients in time to matter. The $100 million increase in NIH funding, $41.5 million in BOLD Infrastructure investment, and $200 million in primary care enhancement represent important commitments, yet they fall short of the $2 billion in annual research funding and comprehensive care infrastructure that experts identify as necessary. The current system—with fragmented primary care, limited diagnostic capacity, geographic disparities, and minimal caregiver support—cannot manage the disease burden of 2050 without structural transformation.

The path forward requires sustained political commitment, strategic allocation of existing resources, and recognition that infrastructure investment in Alzheimer’s care is not a cost to be managed but an investment in preventing a crisis. Families, individuals at risk, healthcare providers, and communities can advocate for expansion of diagnostic services, integration of dementia care pathways into primary care, funding for caregiver support, and access to prevention research. Federal funding must continue to increase, matching the scale of the challenge. Without robust healthcare infrastructure for Alzheimer’s care, the nation will face preventable decline in millions of Americans—the opposite of what modern medicine can achieve.